Cell and Gene Therapy Third-Party Logistics Market Size, Share and Growth Outlook, 2026

Cell and Gene Therapy Third-Party Logistics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cell and Gene Therapy Third-Party Logistics Market size is forecast to increase from $15.86 Billion in 2026 to $38.88 Billion in 2034 at a CAGR of 11.86% between 2026 and 2034.

The Cell and Gene Therapy Third-Party Logistics market report provides detailed analysis and outlook of Cell and Gene Therapy Third-Party Logistics segments including By Service Type (Transportation Services, Warehousing & Storage Services, Packaging and Labeling Services, Regulatory Compliance & Customs Brokerage), By Temperature Range (Cryogenic Storage, Ultra-Low Temperature Storage, Refrigerated Storage, Ambient Storage ), By Product Type (Cell Therapies, Gene Therapies ), By End-User (Biopharmaceutical Companies, Contract Manufacturing Organizations, Clinical Research Organizations, Hospitals & Medical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cell and Gene Therapy Third-Party Logistics (3PL) Industry Overview

Specialized Logistics Infrastructure Supporting Advanced Therapies

The cell and gene therapy third-party logistics industry is evolving rapidly as the commercialization of personalized medicines creates demand for highly specialized transportation, storage, and supply chain management services. Unlike conventional pharmaceutical logistics, cell and gene therapy products often require ultra-low temperature preservation, patient-specific tracking, strict Chain of Identity controls, and synchronized coordination between collection centers, manufacturing facilities, and treatment sites. Third-party logistics providers are expanding infrastructure, strengthening cold-chain capabilities, and developing integrated lifecycle management services to support the growing complexity of advanced therapy supply chains.

Strategic Portfolio Realignment Enhancing Service Specialization

Industry participants are increasingly refining their operational focus to strengthen specialized cell and gene therapy logistics capabilities. Cryoport, Inc. completed the strategic divestiture of its CRYOPDP specialty courier business to DHL Group. This corporate restructuring enables Cryoport to concentrate resources and investment directly on its core biostorage, bioprocessing support, and cell and gene therapy lifecycle management services. At the same time, DHL remains an important global transportation partner, allowing Cryoport to maintain access to extensive international shipping capabilities while sharpening its focus on high-value advanced therapy logistics operations.

Expansion of Global Supply Chain Centers Supporting Clinical Growth

Infrastructure expansion remains a major priority within the cell and gene therapy 3PL industry as developers progress toward late-stage clinical development and commercialization. In its operational update, Cryoport announced the development of two advanced Global Supply Chain Centers designed to support growing demand for specialized logistics services. The expansion includes a dedicated BioServices operations facility in Paris, France, as well as a high-capacity logistics center in Santa Ana, California. These facilities are specifically intended to strengthen support for late-stage clinical trial distribution networks, improve regional logistics coverage, and enhance operational capacity for advanced therapeutic products requiring controlled storage and transportation environments.

Integrated Apheresis and Cryopreservation Logistics Advancing Commercial Operations

A major trend within the industry is the development of integrated logistics platforms capable of linking patient collection sites directly with manufacturing operations. Cryoport's IntegriCell platform network in Belgium and the United States successfully completed its first commercial-scale shipments involving apheresis collections and cryopreserved patient materials. These operations demonstrate a highly coordinated workflow that connects hospital-based collection centers with centralized contract manufacturing facilities while maintaining continuous thermal monitoring throughout transport. The successful execution of these commercial shipments highlights the increasing maturity of specialized cell and gene therapy logistics networks and the growing importance of synchronized end-to-end supply chain management for personalized medicine programs.

Cell and Gene Therapy Third-Party Logistics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cell and Gene Therapy Third-Party Logistics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Cencora, Inc. , Cardinal Health, Inc., McKesson Corporation, EVERSANA, Knipper Health, DHL (LifeConEx), Kuehne + Nagel, Arvato SE, FedEx Corporation, United Parcel Service (UPS Healthcare). The Cell and Gene Therapy Third-Party Logistics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cell and Gene Therapy Third-Party Logistics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cell and Gene Therapy Third-Party Logistics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cell and Gene Therapy Third-Party Logistics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cell and Gene Therapy Third-Party Logistics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cell and Gene Therapy Third-Party Logistics Market Competitive Benchmarking and Company Analysis

Leading companies in Cell and Gene Therapy Third-Party Logistics industry include- Cencora, Inc. , Cardinal Health, Inc., McKesson Corporation, EVERSANA, Knipper Health, DHL (LifeConEx), Kuehne + Nagel, Arvato SE, FedEx Corporation, United Parcel Service (UPS Healthcare). The Cell and Gene Therapy Third-Party Logistics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cell and Gene Therapy Third-Party Logistics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cell and Gene Therapy Third-Party Logistics market remains one of the strongest-performing segments in the country.
The US Cell and Gene Therapy Third-Party Logistics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cell and Gene Therapy Third-Party Logistics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cell and Gene Therapy Third-Party Logistics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cell and Gene Therapy Third-Party Logistics markets

Canada's strong Cell and Gene Therapy Third-Party Logistics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cell and Gene Therapy Third-Party Logistics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cell and Gene Therapy Third-Party Logistics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cell and Gene Therapy Third-Party Logistics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cell and Gene Therapy Third-Party Logistics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cell and Gene Therapy Third-Party Logistics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cell and Gene Therapy Third-Party Logistics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cell and Gene Therapy Third-Party Logistics sales through 2034

France Cell and Gene Therapy Third-Party Logistics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cell and Gene Therapy Third-Party Logistics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cell and Gene Therapy Third-Party Logistics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cell and Gene Therapy Third-Party Logistics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cell and Gene Therapy Third-Party Logistics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cell and Gene Therapy Third-Party Logistics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cell and Gene Therapy Third-Party Logistics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cell and Gene Therapy Third-Party Logistics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cell and Gene Therapy Third-Party Logistics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cell and Gene Therapy Third-Party Logistics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cell and Gene Therapy Third-Party Logistics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cell and Gene Therapy Third-Party Logistics Market Segmentation

By Service Type
Transportation Services
Warehousing & Storage Services
Packaging and Labeling Services
Regulatory Compliance & Customs Brokerage
By Temperature Range
Cryogenic Storage
Ultra-Low Temperature Storage
Refrigerated Storage
Ambient Storage
By Product Type
Cell Therapies
Gene Therapies
By End-User
Biopharmaceutical Companies
Contract Manufacturing Organizations
Clinical Research Organizations
Hospitals & Medical Centers

Top Companies in Cell and Gene Therapy Third-Party Logistics Industry

Cencora, Inc.
Cardinal Health, Inc.
McKesson Corporation
EVERSANA
Knipper Health
DHL (LifeConEx)
Kuehne + Nagel
Arvato SE
FedEx Corporation
United Parcel Service (UPS Healthcare)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

MoCRA Compliance as a Competitive Advantage in the US

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025